Fig. 3

Lenalidomide treatment of MM cells affected the steady-state levels of CRBN and AGO2. a CRBN and AGO2 protein expression in My5.LV cell or in My5.CRBN cell. 100 μg of total proteins from whole cell lysates were loaded in each lane and analyzed by western blot. b The steady-state levels of AGO2, CRBN and β-actin were compared between My5.LV and My5.CRBN cells. c & d Relative levels of AGO2, CRBN and β-actin. Cells were treated with either DMSO (control) or 10 μM lenalidomide (LEN) for the time indicated in the figure. 100 μg of total proteins from My5.LV cells (c) or My5.CRBN cells (d) were loaded in each lane and analyzed by western blot. e & f Comparison of the protein expression between the samples treated with either DMSO or lenalidomide. The steady-state levels of AGO2, CRBN and β-actin in My5.LV cells (e) or in My5.CRBN cells (f) were compared between the treatments with either DMSO (considered as 1.0) or lenalidomide. g Quantitative analysis of AGO2 mRNA or CRBN mRNA. Total RNA was isolated from My5.LV and My5.CRBN cells treated with either DMSO or 10 μM lenalidomide for six days and used to do quantitative polymerase chain reaction (qPCR). h Relative levels of AGO2, CRBN and β-actin in MM1.S.Res cells treated with either DMSO or 10 μM lenalidomide. MM1.S.Res cells were treated with either DMSO or 10 μM lenalidomide for six days. 100 μg of total proteins from these treated cells were loaded in each lane and analyzed by western blot